Cardiac Mapping Market Size and Share

Cardiac Mapping Market (2025 - 2030)
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Cardiac Mapping Market Analysis by Mordor Intelligence

The cardiac mapping market size reached USD 2.17 billion in 2025 and is forecast to climb to USD 3.34 billion by 2030, translating to a CAGR of 8.99%. North America leads with 43.12% revenue share in 2024, yet Asia-Pacific delivers the fastest 9.54% CAGR as hospital networks add electrophysiology capacity and embrace artificial-intelligence-enabled platforms. Demand accelerates because atrial fibrillation affects more than 60 million people worldwide, compelling providers to adopt precision mapping systems that shorten procedures and cut readmissions. Contact technologies still command 64.23% share, but non-contact innovations are expanding at 10.43% CAGR on the back of ultrasound and body-surface algorithms that reduce fluoroscopy time. Competitive intensity has elevated since 2024 as manufacturers introduce dual-energy ablation and AI-guided navigation, while hospitals pivot toward same-day discharge models that trim per-case costs by EUR 850-1,301. Reimbursement headwinds—such as a 2.8% CMS conversion-factor cut for 2025—push administrators to extract higher throughput and verifiable outcomes from every device purchase.

Key Report Takeaways

  • By product type, contact mapping systems held 64.23% of the cardiac mapping market share in 2024, while non-contact platforms posted the fastest 10.43% CAGR through 2030.
  • By indication, atrial fibrillation accounted for 58.54% of the cardiac mapping market size in 2024; ventricular tachycardia is projected to expand at an 11.89% CAGR during 2025-2030.
  • By end-user, tertiary hospitals led with 55.47% share in 2024, whereas ambulatory surgical centers are forecast to grow at an 11.76% CAGR to 2030.
  • By geography, North America captured 43.12% revenue share in 2024; Asia-Pacific is advancing quickest at a 9.54% CAGR throughout the forecast period.

Segment Analysis

By Product Type: Contact Systems Dominate Despite Non-Contact Innovation

Contact platforms delivered 64.23% of the cardiac mapping market size in 2024 owing to widespread clinical familiarity, robust reimbursement, and improvements such as 64-electrode grids that yield sub-millimeter resolution. Abbott’s TactiCath catheter registers 0.3 gram precision that helps operators titrate energy safely. The segment’s momentum is fortified by integration with popular ablation generators, ensuring procedural continuity.

Non-contact modalities are advancing at a 10.43% CAGR because AI body-surface algorithms and ultrasound acoustical sensors can reconstruct 3-D chambers without extensive catheter manipulation, thereby reducing fluoroscopy exposure. Basket and multi-electrode arrays provide panoramic data that identifies extra-pulmonary triggers overlooked by point-by-point systems. Hybrid workflows merge contact accuracy for lesion validation with global non-contact scans that guide strategy, illustrating technology convergence that will sustain segment diversity within the cardiac mapping market.

Cardiac Mapping Market: Market Share by Product Type
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Indication: Atrial Fibrillation Leadership Faces VT Challenge

Atrial fibrillation represented 58.54% of the cardiac mapping market share during 2024 on the strength of a vast patient pool and standardized procedural pathways. Over 12 million Americans are projected to carry an AF diagnosis within ten years, guaranteeing steady procedural volumes. PFA platforms already post 88% arrhythmia-free survival at one year, enhancing position.

Ventricular tachycardia is growing fastest at 11.89% CAGR because substrate mapping innovations like the S3 technique raise long-term success to 77.9%[3]Ferdinand Kuschyk, “S3 Mapping Technique for VT,” Journal of the American College of Cardiology, jacc.org. Although VT cases are fewer, they carry higher mortality risk, motivating tertiary centers to procure sophisticated 3-D systems that image intramural circuits. Personalised AI-guided maps now tailor lesions based on real-time conduction patterns, narrowing the efficacy gap between VT and AF treatments and expanding the cardiac mapping market size among high-acuity patients.

Cardiac Mapping Market: Market Share by Indication
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By End-User: Hospital Dominance Shifts Toward Ambulatory Care

Tertiary hospitals captured 55.47% revenue because they house multidisciplinary teams, hybrid operating rooms, and advanced imaging that underpin complex ablations. They act as reference sites where vendors launch upgrades and collect early-use data.

Ambulatory surgical centers are projected to grow at 11.76% CAGR since same-day discharge protocols have proven safe and cost-efficient. Portable consoles, simplified workflows, and regulatory discussion around ASC inclusion for catheter ablations accelerate this move. Electrophysiology labs embedded within community hospitals compete on volume efficiency, while academic institutes emphasize first-in-human trials that seed future upgrades. This care-setting diversification enlarges the cardiac mapping market by deploying systems beyond flagship institutions.

Geography Analysis

North America booked 43.12% revenue in 2024 thanks to mature reimbursement and early PFA clearances that encourage rapid technology refresh cycles. US centers participate in pivotal trials for dual-energy ablation and AI mapping, securing clinical leadership. Moderate growth through 2030 reflects saturation at top hospitals, though outpatient expansion offsets plateau effects.

Asia-Pacific delivers the highest 9.54% CAGR because cardiovascular disease burdens rise in tandem with economic growth. Fortis Healthcare’s USD 156 million expansion that adds AI-equipped cath labs typifies regional investment. Chinese device firms target FDA and CE pathways, intensifying price competition while broadening product availability. Japan, South Korea, and Australia leverage aging demographics and sophisticated insurance systems to adopt new modalities quickly.

Europe sustains incremental gains as payers scrutinize cost-utility yet reward proven innovations through harmonized regulatory channels. Germany, the United Kingdom, and France absorb most installations, while Italy and Spain emphasize regional equity in access. Brexit mildly disrupts supply chains but clinical collaboration endures. Middle East & Africa and South America form smaller bases yet offer long-run upside as public health budgets climb. Overall, diversified regional trajectories collectively reinforce global expansion of the cardiac mapping market.

Cardiac Mapping Market CAGR (%), Growth Rate by Region
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

Biosense Webster, Abbott, Boston Scientific, and Medtronic anchor a moderately consolidated field where platform breadth and R&D scale drive share. Since 2024, the race to commercialize PFA and AI navigation spawned approvals like Medtronic’s Affera and Boston Scientific’s FARAPULSE, resetting competitive benchmarks. Collaborations flourish: Abbott links with iCardio.ai, while Volta Medical teams with GE Healthcare to embed machine learning into familiar consoles.

Acquisitions underline strategic urgency; Boston Scientific’s Cortex buy strengthens computational mapping for PFA catheters. Niche competitors such as Stereotaxis promote robotically navigated magnetic catheters, aiming at radiation-free precision. Vektor Medical markets purely computational arrhythmia localization that overlays any mapping system, allowing capital-light upgrades.

Price pressure and cybersecurity mandates—FDA released updated guidance in June 2025—drive convergence around secure, upgradable architectures. Vendors that showcase authenticated encryption, cloud update pathways, and proven reductions in procedure time improve tender success. Consequently, product differentiation hinges on measurable efficiency, integrated safety features, and flexible business models rather than hardware alone, shaping sustainable leadership in the cardiac mapping market.

Cardiac Mapping Industry Leaders

  1. Medtronic Plc

  2. Boston Scientific Corporation

  3. Acutus Medical

  4. Johnson & Johnson

  5. Abbott

  6. *Disclaimer: Major Players sorted in no particular order
Cardiac Mapping Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Recent Industry Developments

  • July 2025: Boston Scientific secured FDA approval for expanded FARAPULSE labeling covering persistent AF after the ADVANTAGE AF trial yielded an 85.3% success rate.
  • June 2025: Abbott received CE Mark for the Volt Pulsed Field Ablation System, achieving 99.1% PV isolation on fewer energy applications.
  • April 2025: Medtronic reported 88% arrhythmia-free survival from Sphere-360 single-shot PFA trials in paroxysmal AF patients.
  • March 2025: Stereotaxis filed a 510(k) for the MAGiC Sweep robotically navigated high-density mapping catheter with 20 electrodes.
  • November 2024: Johnson & Johnson MedTech obtained FDA clearance for the VARIPULSE PFA platform integrated with CARTO 3 mapping, reaching 85% primary effectiveness.
  • October 2024: Medtronic won FDA approval for the dual-energy Affera Mapping and Ablation System with Sphere-9 catheter.

Table of Contents for Cardiac Mapping Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Cardiovascular Diseases
    • 4.2.2 Advancements in Electrophysiology Mapping Technologies
    • 4.2.3 Increasing Adoption of Minimally Invasive Ablation Procedures
    • 4.2.4 Favorable Regulatory and Reimbursement Policies
    • 4.2.5 Expansion of Cardiac Electrophysiology Infrastructure in Emerging Markets
    • 4.2.6 Integration of Artificial Intelligence and Cloud Analytics in Mapping Workflows
  • 4.3 Market Restraints
    • 4.3.1 Shortage of Skilled Electrophysiologists
    • 4.3.2 High Capital and Procedural Costs
    • 4.3.3 Cybersecurity and Patient Data Privacy Concerns
    • 4.3.4 Semiconductor Supply Chain Vulnerabilities
  • 4.4 Regulatory Landscape
  • 4.5 Technological Outlook (Emerging Modalities)
  • 4.6 Porter's Five Forces Analysis
    • 4.6.1 Threat Of New Entrants
    • 4.6.2 Bargaining Power Of Buyers/Consumers
    • 4.6.3 Bargaining Power Of Suppliers
    • 4.6.4 Threat Of Substitute Products
    • 4.6.5 Intensity Of Competitive Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Product Type
    • 5.1.1 Contact Mapping Systems
    • 5.1.1.1 Conventional RF Contact Catheters
    • 5.1.1.2 Contact-Force Sensing Catheters
    • 5.1.1.3 High-Density Grid Catheters
    • 5.1.2 Non-Contact Mapping Systems
    • 5.1.2.1 Basket & Multielectrode Arrays
    • 5.1.2.2 Ultrasound / Acoustical Mapping
    • 5.1.2.3 AI-Based Body-Surface Mapping
  • 5.2 By Indication
    • 5.2.1 Atrial Fibrillation
    • 5.2.2 Atrial Flutter
    • 5.2.3 Ventricular Tachycardia
    • 5.2.4 Supraventricular Tachycardia
  • 5.3 By End-User
    • 5.3.1 Tertiary Hospitals
    • 5.3.2 Electrophysiology & Cath Labs
    • 5.3.3 Ambulatory Surgical Centres
    • 5.3.4 Academic & Research Institutes
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East & Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East & Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 Biosense Webster (Johnson & Johnson)
    • 6.3.2 Abbott
    • 6.3.3 Boston Scientific Corporation
    • 6.3.4 Medtronic Plc
    • 6.3.5 Acutus Medical
    • 6.3.6 Koninklijke Philips
    • 6.3.7 MicroPort Scientific
    • 6.3.8 Lepu Medical
    • 6.3.9 AngioDynamics
    • 6.3.10 Kardium
    • 6.3.11 APN Health
    • 6.3.12 BioSig Technologies
    • 6.3.13 Vektor Medical
    • 6.3.14 HeartBeam Inc.
    • 6.3.15 AtriCure
    • 6.3.16 Volta Medical
    • 6.3.17 CathVision
    • 6.3.18 Imricor Medical
    • 6.3.19 OSYPKA AG
    • 6.3.20 Biotronik

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment

Global Cardiac Mapping Market Report Scope

As per the scope, cardiac mapping is an electrophysiology study that aims to understand the cause of heart rhythm problems like arrhythmia. Mapping the heart's electrical activity is critical for diagnosing and treating heart disease.

The cardiac mapping market is segmented by type, indication, and geography. By type, the market is segmented into contact cardiac mapping systems and non-contact cardiac mapping systems. By indication, the market is segmented into atrial fibrillation, atrial flutter, and other indications. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (USD) for the above segments.

By Product Type
Contact Mapping Systems Conventional RF Contact Catheters
Contact-Force Sensing Catheters
High-Density Grid Catheters
Non-Contact Mapping Systems Basket & Multielectrode Arrays
Ultrasound / Acoustical Mapping
AI-Based Body-Surface Mapping
By Indication
Atrial Fibrillation
Atrial Flutter
Ventricular Tachycardia
Supraventricular Tachycardia
By End-User
Tertiary Hospitals
Electrophysiology & Cath Labs
Ambulatory Surgical Centres
Academic & Research Institutes
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America
By Product Type Contact Mapping Systems Conventional RF Contact Catheters
Contact-Force Sensing Catheters
High-Density Grid Catheters
Non-Contact Mapping Systems Basket & Multielectrode Arrays
Ultrasound / Acoustical Mapping
AI-Based Body-Surface Mapping
By Indication Atrial Fibrillation
Atrial Flutter
Ventricular Tachycardia
Supraventricular Tachycardia
By End-User Tertiary Hospitals
Electrophysiology & Cath Labs
Ambulatory Surgical Centres
Academic & Research Institutes
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa GCC
South Africa
Rest of Middle East & Africa
South America Brazil
Argentina
Rest of South America

Key Questions Answered in the Report

How large will the cardiac mapping market be by 2030?

Forecasts place it at USD 3.34 billion, reflecting an 8.99% CAGR from 2025.

Which region grows fastest for cardiac mapping technologies?

Asia-Pacific leads with a projected 9.54% CAGR through 2030 as hospitals expand electrophysiology capacity.

What segment currently dominates cardiac mapping systems?

Contact platforms held 64.23% share in 2024 due to clinician familiarity and broad reimbursement.

Which arrhythmia indication is expanding most rapidly?

Ventricular tachycardia procedures are set to rise at an 11.89% CAGR thanks to improved substrate mapping.

How does pulsed field ablation influence economics?

Analyses show EUR 850-1,301 savings per patient because of shorter procedure times and reduced complications.

Are outpatient settings gaining share in ablation volumes?

Yes, ambulatory surgical centers exhibit an 11.76% CAGR as same-day discharge protocols demonstrate clinical equivalence.

Page last updated on:

Cardiac Mapping Report Snapshots